This startup is bringing photos—and even video—to 911 calls
But 911 systems, largely designed for the era of landlines, don't typically allow for those luxuries, even when callers are trying to communicate address information from a noisy environment or share a photo of an ongoing emergency.
A startup called Prepared is working to change that, helping emergency call takers communicate more efficiently with people in situations where every second matters by enabling text, photo, and video communication and providing AI tools to transcribe and even translate conversations in real time.
Cofounder and CEO Michael Chime says he had initially focused on providing an app to help schools during emergencies, having grown up near to a school shooting. During the COVID pandemic, when schools were closed, he communicated with school districts about additional features they might want, and several mentioned difficulty sharing detailed data with 911 centers during an emergency.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
7 hours ago
- Business Wire
LINEAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Lineage, Inc. and Announces Opportunity for Investors with Substantial Losses to Lead the Lineage Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)-- Robbins Geller Rudman & Dowd LLP announces that purchasers of Lineage, Inc. (NASDAQ: LINE) common stock in or traceable to the registration statement used in connection with Lineage's July 2024 initial public offering (the 'IPO'), have until September 30, 2025 to seek appointment as lead plaintiff of the Lineage class action lawsuit. Captioned City of St. Clair Shores Police and Fire Retirement System v. Lineage, Inc., No. 25-cv-12383 (E.D. Mich.), the Lineage class action lawsuit charges Lineage and certain of its top executives, directors, IPO underwriters, and IPO sponsor with violations of the Securities Act of 1933. If you suffered substantial losses and wish to serve as lead plaintiff of the Lineage class action lawsuit, please provide your information here: CASE ALLEGATIONS: Lineage is a Maryland REIT focused on temperature-controlled cold-storage facilities. In the July 2024 IPO, Lineage sold over 65 million shares of Lineage common stock to investors at $78 per share, raising more than $5 billion in gross offering proceeds. The Lineage class action lawsuit alleges that the registration statement was false and/or misleading and/or failed to disclose that: (i) Lineage was then experiencing sustained weakening in customer demand, as additional cold-storage supply had come on line, Lineage's customers destocked a glut of excessive inventory built up during the COVID-19 pandemic, and Lineage's customers shifted to maintaining leaner cold-storage inventories on a go-forward basis in response to changed consumer trends; (ii) Lineage had implemented price increases in the lead-up to the IPO that could not be sustained in light of the weakening demand environment facing Lineage; (iii) Lineage was unable to effectively counteract the adverse trends listed above through the use of minimum storage guarantees or as a result of operational efficiencies, technological improvements, or its purported competitive advantages; (iv) as a result, rather than enjoying stable revenue growth, high occupancy rates, and steady rent escalation as represented in the registration statement, Lineage was in fact suffering from stagnant or falling revenue, occupancy rates, and rent prices; and (v) consequently, Lineage's financial results, business operations, and prospects were materially impaired. Since the IPO, the price of Lineage stock has fallen to lows near $40 per share. The price of Lineage stock has remained substantially below the IPO price at the time of the filing of the complaint. The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint by clicking here. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Lineage common stock in or traceable to the registration statement issued in connection with Lineage's IPO to seek appointment as lead plaintiff in the Lineage class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Lineage class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Lineage class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Lineage class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.
The Hill
8 hours ago
- The Hill
CDC bars expert groups from advising on vaccines
Click in for more news from The Hill{beacon} Health Care Health Care The Big Story CDC bars expert groups from advising on vaccines The Centers for Disease Control and Prevention (CDC) told some expert groups that they will no longer be able to help review scientific data used to issue vaccine recommendations. © APSome members of the Advisory Committee on Immunization Practice's (ACIP) working groups, including physician groups and infectious disease specialists, were sent e-mails late Thursday notifying them that they will no longer serve on the subcommittees. The groups were removed from the subcommittees because they were deemed biased by the Trump administration, according to a copy of the email shared with The Hill. "By definition, Liason organizations are special interest groups and therefore are expected to have a 'bias' based on their constituency/and or population that they represent," the email reads. "It is important that the ACIP Workgroup activities remain free of influence from any special interest groups so ACIP workgroups will no longer include Liason organizations." Eight of the advisory groups released a joint statement Friday saying they are 'deeply disappointed' that they are now barred from informing the development of vaccine recommendations. 'For decades liaisons from our organizations have reviewed published and unpublished data and literature related to vaccine efficacy, effectiveness, and safety and provided unbiased input for ACIP's consideration,' the statement reads. 'To remove our deep medical expertise from this vital and once transparent process is irresponsible, dangerous to our nation's health, and will further undermine public and clinician trust in vaccines.' The groups, which include the American Medical Association, as well as the Infectious Diseases Society of America, called on the Trump administration to reconsider their exclusion from the vaccine review process. A spokesperson for the Department of Health and Human Services (HHS), which oversees the CDC, said that experts will continue to be included in the review process based on 'relevant experience and expertise." 'Under the old ACIP, outside pressure to align with vaccine orthodoxy limited asking the hard questions,' the spokesperson wrote. 'The old ACIP members were plagued by conflicts of interest, influence and bias.' The notice is the latest move from the Trump administration to shake up the nation's vaccine policy and is another major change to the CDC's advisory panel on vaccines. HHS Secretary Robert F. Kennedy Jr abruptly fired all 17 sitting members of ACIP in early June, accusing them of having conflicts of interest and rubber-stamping decisions related to the COVID-19 vaccine. He then replaced the panel with eight hand-picked appointees, including some vaccine skeptics. Welcome to The Hill's Health Care newsletter, we're Nathaniel Weixel, Alejandra O'Connell-Domenech — every week we follow the latest moves on how Washington impacts your health. Did someone forward you this newsletter? Subscribe here. Essential Reads How policy will be impacting the health care sector this week and beyond: Most adults do not plan on getting COVID-19 shot amid vaccine policy changesMore than half of American adults — 59 percent — say they do not expect to get the COVID-19 booster shot this autumn, according to new poll findings from health care policy group KFF. Poll results show 23 percent of U.S. adult respondents said they will 'probably not' get the vaccine, while 37 percent said they will 'definitely not' get the shot. Americans who said they will 'probably' or 'definitely' not get the shot were … Full Story Blue states challenge Trump's restrictions on gender-affirming care More than a dozen Democratic attorneys general announced a lawsuit challenging recent moves by President Trump's administration to severely restrict access to gender-affirming health care for anyone under 19, including in states where treatment is legal and protected by law. Full Story Fired vaccine board members warn of fallout from RFK Jr. policiesRecently removed members of a Centers for Disease Control and Prevention (CDC) vaccine advisory panel warn that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.'s move to replace them shows he is 'abandoning' rigorous scientific review and open deliberation. Kennedy fired all 17 sitting members of the Advisory Committee on Immunization Practices (ACIP) in early June, accusing members of having conflicts of … Full Story In Other News Branch out with a different read: Number of Texans receiving out-of-state abortions quadrupled between 2021 and 2023 AUSTIN (KXAN) — Texans who sought an abortion out of state more than quadrupled between 2021 and 2023 after a state law went into effect that bans the procedure in almost all cases. Data from the Texas Health and Human Services Commission (HHSC) shows at least 7,844 Texas residents received an abortion in a different state in 2023, up from 4,718 in 2022 and 1,712 in 2021. Still the total number of abortions for Texas residents … Full Story Around the Nation Local and state headlines on health care:More than 2,000 DACA recipients in California to lose health insurance (the San Francisco Chronicle) Some rural Texas seen THC as a lifeline for their health and economy (The Texas Tribune) Illinois becomes first state to require mental health screenings for students (ABC) What We're Reading Health news we've flagged from other outlets: Medicare, Medicaid plans to experiment with covering weight loss drugs (The Washington Post) Wildfire smoke and unhealthy air fill the Midwest before spreading to the East (The Washington Post) Remember running a mile in school? The Presidential Fitness Test is coming back (NPR) You're all caught up. See you next week! Close Thank you for signing up! Subscribe to more newsletters here The latest in politics and policy. Direct to your inbox. Sign up for the Health Care newsletter Subscribe
Epoch Times
8 hours ago
- Epoch Times
Most Americans Won't Get COVID-19 Booster This Fall, Survey Says
A majority of Americans said they will likely not receive a COVID-19 booster vaccine this fall, according to a poll released Friday. A survey from the health care organization KFF found that 59 percent of respondents said they either will not or likely will not receive the booster dose. Around 37 percent said they would 'definitely not' receive the shot, while 23 percent said they would 'probably not get' the shot.
